<DOC>
	<DOCNO>NCT03096717</DOCNO>
	<brief_summary>Chronic intestinal inflammation produce dysplasia frequently normal population . The therapy protect change , rule dysplasia . It known effect different therapy protection .</brief_summary>
	<brief_title>Dysplasia Inflammatory Chronic Idiopathic Colitis Long-standing</brief_title>
	<detailed_description>The literature data show inflammatory bowel disease ( rectal ulcerative colitis Crohn 's disease ) determine increase risk develop dysplasia cancer colon rectum , chronic inflammation fee , difference two disease arise . The progression normal mucosa dysplasia cancer rapid adenoma-carcinoma sequence . In patient idiopathic chronic inflammatory colitis drug therapy use reduce incidence dysplasia . A systematic review conclude favor chemo preventive effect mesalazine . In case , report protective association use mesalazine cancer associate colitis ( colitis Associated carcinoma CAC ) odds ratio 0.51 per CAC / dysplasia . This data , subsequent study , include recent one , remain controversial . The introduction biological drug treatment patient inflammatory bowel disease ( IBD ) change quality life also natural history disease . It known biological drug improve clinical history disease change incidence dysplasia colorectal cancer . The treatment idiopathic inflammatory bowel disease ( IBD ) , last decade see profound change , , use biological drug frequent moderate-severe form , especially extend . Mesalazine indication mild moderate form therapy .</detailed_description>
	<mesh_term>Colitis</mesh_term>
	<criteria>long stand colonic inflammatory bowel disease clinical , endoscopic histological remission completeness data important comorbidities family history colorectal cancer insufficient data</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>